Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001209191-24-003270 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-13 | 2024-02-09 | LYEL | Newton Charles W. | CFO | A - Grant | $0.00 | +40.0K | 48.7K | +458% | $0 |
| D | 2024-02-13 | 2024-02-09 | LYEL | Newton Charles W. | CFO | A - Grant | $0.00 | +400.0K | 400.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | A | A | 40,000 | $0.00 | 48,729 | D | — | — | (F1) The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 2,941 shares acquired on May 18, 2022, 5,787 shares acquired on May 18, 2023 and 1 share acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan. |
| 2 | Derivative | Stock Option (right to buy) | 2024-02-09 | A | A | 400,000 | $0.00 | 400,000 | D | $1.80 · — to 2034-02-08 | 400,000 Common Stock | (F3) 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months. |